Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Patent protection of traditional knowledge and biological material
Asia
Therapeutic substances used under the folk medicine practices of what is known as ‘traditional knowledge’ are protected by special provisions under Indian patent law. Archana Shanker and Vidisha Garg explore the pros and cons.   1 April 2013
Slow but positive change? The evolution of section 3d
Asia
New definitions of efficacy are helping to clarify pharmaceutical patent challenges under the notorious Section 3d of the Indian Patents Act, says Rahul Vartak.   1 April 2013
The likely role of the UPC in pharma patent litigation
Big Pharma
The recent agreement on a Unified Patent Court in Europe raises questions for patent holders in all industries. Trevor Cook looks at the potential impact on pharmaceutical patent litigation.   28 March 2013
Big Pharma
Gordon Wright reviews the key SPC cases as Europe’s SPC Regulation for medicinal products approaches its 21st birthday.   28 March 2013
Big Pharma
When most people hear the word counterfeiting, they think of fashion, but as Bruce Longbottom of Eli Lilly and Company explains, drugs are a key target too.   28 March 2013
Americas
For a young innovation company, IP protection is all about ensuring comprehensive coverage. LSIPR spoke to David Diamond of MannKind Corporation about its threats and opportunities.   28 March 2013
Americas
UK pharmaceutical company AstraZeneca has reached a settlement with Actavis and Egis Pharmaceuticals that delays the release of generic versions of its cholesterol treatment Crestor.   27 March 2013
Americas
AstraZeneca has signed a five-year licensing deal with Moderna Therapeutics, a US biotechnology company specialising in drugs using RNA therapeutics.   22 March 2013
Americas
Pharmaceutical companies Bayer, Intendis and Intraserv have filed a patent infringement lawsuit against Glenmark after it applied to market a generic version of rosacea treatment Finacea.   15 March 2013
Americas
Generic drug maker Mylan has struck a deal with pharma companies Shionogi and Andrx to resolve a patent dispute over their diabetes drug Fortamet.   15 March 2013